Skip to content

IPHA

Innate Pharma SA

NASDAQ · Healthcare · Biotechnology · FR

$1.90
−0.52%
Ask drillr

Year over year

Reported trailing growth

Revenue
-78.9%
EBITDA
-13.2%
EBIT
+1.7%
EPS
+7.3%
Free cash flow
-1.7%
Operating cash flow
-1.7%

Forward estimates

Based on analyst estimates

Revenue
+81.5%
EBITDA
+61.1%
EPS
+52.5%

Three-year CAGR

Revenue
-63.6%
EBITDA
+7.0%
EBIT
-3.6%
Net income
+0.6%
EPS
+13.1%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026